The 2023 ESMO annual meeting took place from OCtober 20th to October 24 2023, in Madrid, Spain. This year’s event was primarily an in-person event with virtual broadcasts available. The program at a glance is available here. In the present report we will be assessing the impact of the conference online from the view of HCPs :
- Conditions and drugs most discussed during the listening period
- Overview of clinical trials and discussions that have generated the most engagement
Scope
The scope of the analysis is focused on mentions coming worldwide.*
A total of 65K mentions were recorded during the listening period from October 13th, 2023, to November 7th, 2023 (one week before and two weeks after the conference).
All mentions came from Twitter.
A total of 7K unique authors were identified.
*#esmo23 OR #esmo2023 OR (esmo NEAR/2 (2023 OR 23))
Methodology
Volume of conversations
Volume of mentions overtime ESMO 2023
The overall number of mentions remained stable only growing a modest 0,23% compared to 2022. The peak of conversations happened during the conference, representing 74% of mentions recorded during the listening period.
ESMO 2023: Focus On HCPs
EV-302 is far and away the trial that received the most engagement during this years’ ESMO edition.
Results which showed significantly extended OS and PFS with a combination of enfortumab vedotin-ejfv and Keytruda (pembrolizumab) in first-line advanced bladder cancer were deemed to be groundbreaking, practice-changing and a win by HCPs.
Most mentioned cancers
Volume of mentions HCPs
Most mentioned clinical trials
Most mentioned molecules
Top posts from HCPs per engagement
